Skip to Main Content
Diseases of the Musculoskeletal System, Phase III

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)

What is the purpose of this trial?

Brief Summary:

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.

  • Trial with
    Ra Pharmaceuticals, Inc.
  • Ages
    40 years - 80 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Richard Nowak

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    10/08/2024
  • Study HIC
    #2000026786